Menu
X

**Chinese Medical Team Releases Dual-Target CAR-T Data: 100% Complete Remission Rate in High-Risk MM Patients**

**Chinese Medical Team Releases Dual-Target CAR-T Data: 100% Complete Remission Rate in High-Risk MM Patients**

High-Risk MM

High-Risk MM

#CARTTherapy #MultipleMyeloma #BCMA #CD19 #JAMAOncology #MM #HRMM #DualTarget

Once again, a Chinese medical team is at the forefront of innovation, making significant strides in the field of CAR-T cell therapy. A recent study published in *JAMA Oncology* (B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma) revealed remarkable results for the dual-target BCMA/CD19 CAR-T therapy in high-risk newly diagnosed multiple myeloma (NDMM) patients. In this study, all 19 participants achieved stringent complete remission (sCR) and were found to be minimal residual disease (MRD) negative, resulting in an astounding 100% remission rate.

**CAR-T Therapy: A Breakthrough in Hematologic Cancer Treatment**

Multiple myeloma (MM) is a challenging hematologic cancer, particularly for patients with high-risk features, where traditional treatments often show limited efficacy. CAR-T cell therapy is an innovative immunotherapy that reprograms a patient’s own T cells to recognize and attack cancer cells. In recent years, this therapy has shown significant success in treating leukemia, lymphoma, and relapsed/refractory MM (RRMM). The latest study further demonstrates that dual-target CAR-T therapy, focusing on BCMA and CD19, can significantly improve the prognosis for high-risk MM patients.

**The Impressive Results of China’s Dual-Target CAR-T Therapy**

The CAR-T therapy used in this study, GC012F, targets both B-cell maturation antigen (BCMA) and CD19 surface antigens, showing powerful anti-tumor effects. Every patient in the study not only achieved complete remission after treatment but also maintained a long-term MRD-negative status, meaning that traces of cancer cells were nearly undetectable post-therapy.

More importantly, the study highlighted the swift effectiveness of the Chinese GC012F therapy—patients reached their first complete remission in a median time of just 84 days, with MRD-negative status achieved in as little as 28 days. This rapid anti-tumor response provides a crucial treatment window for patients, significantly improving their prognosis.

**Safety and Future Prospects**

In addition to its impressive efficacy, GC012F demonstrated favorable safety. Only 27% of patients experienced mild to moderate cytokine release syndrome (CRS), and no cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. This is in stark contrast to previous studies in relapsed/refractory patients, where CRS rates were higher, highlighting the safety advantage of this therapy in newly diagnosed patients.

Though the study sample size was small, these findings bring new hope for high-risk multiple myeloma patients. As larger clinical trials are conducted and combination therapies are explored, this therapy has the potential to offer better survival outcomes for more patients.

**Conclusion**

China’s CAR-T cell therapy research continues to lead the way in hematologic cancer treatment. The success of the BCMA/CD19 dual-target CAR-T therapy not only demonstrates its strong efficacy in high-risk multiple myeloma but also provides a new direction for treating hematologic cancers globally. As research deepens, we anticipate that this groundbreaking therapy will bring new life-saving opportunities to more patients.

This breakthrough in Chinese CAR-T therapy represents not only scientific progress but also underscores China’s pivotal role in the global fight against cancer.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #Immunotherapy #MedicalInnovation #CancerResearch #ChinaHealthcare #HematologicCancer #CancerBreakthrough

By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

© Copyright 2023 Advanced Medicine In China. All rights reserved.